REVIEW PAPER
Myeloid-derived suppressor cells in ovarian cancer: friend or foe?
Submission date: 2016-08-04
Acceptance date: 2016-09-07
Publication date: 2017-12-30
Cent Eur J Immunol 2017;42(4):383-389
KEYWORDS
ABSTRACT
Although previous decades contributed to major progress in targeted therapy of many malignancies, the treatment of gynaecological cancers remains a challenging task. In the evidence of rising cancer mortality, the search for new methods of treatment is a dire need. Exploring the mechanisms of interaction between tumour cells and host immune response may allow the introduction of new, effective therapies – not as toxic and far more efficient than conventional methods of cancer treatment. Epithelial ovarian cancer (EOC) is typically diagnosed at advanced stages. Its incidence and mortality rate is high. Powerful diagnostic tools for this kind of cancer are still under investigation. Multiple mechanisms existing in the ovarian tumour network create a specific immunosuppressive microenvironment, in which accumulation of myeloid-derived suppressor cells (MDSCs) may be a critical component for diagnosis and treatment. This review attempts to verify current knowledge on the role of MDSCs in EOC.
REFERENCES (84)
1.
Kebelmann-Betzing C, Korner G, Badiali L, et al. (2001): Characterization of cytokine, growth factor receptor, costimulatory and adhesion molecule expression patterns of bone marrow blasts in relapsed childhood B cell precursor ALL. Cytokine 13: 39-50.
2.
Łuczyński W, Stasiak-Barmuta A, Iłendo E, et al. (2006): Low expression of costimulatory molecules and mRNA for cytokines are important mechanisms of immunosuppression in acute lymphoblastic leukemia in children? Neoplasma 53: 301-304.
3.
Gabrilovich DI, Bronte V, Chen SH, et al. (2007): The terminology issue for myeloid-derived suppressor cells. Cancer Res 67: 425-426.
4.
Bronte V, Apolloni E, Cabrelle A, et al. (2000): Identification of CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells. Blood 96: 3838-3846.
5.
Zea AH, Rodriquez PC, Atkins MB, et al. (2005): Arginase- producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65: 3044-3048.
6.
Billiau AD, Fevery S, Rutgeerts O, et al. (2003): Transient expansion of Mac1+Ly6-G+Ly6-C+ early myeloid cells with suppressor activity in spleens of murine radiation marrow chimeras: possible implications for the graft-versus-host and graft-versus-leukemia reactivity of donor lymphocyte infusions. Blood 102: 740-748.
7.
Bunt SK, Sinha P, Clements VK, et al. (2006): Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 176: 284-290.
8.
Zhang Q, Fujino M, Xu J, Li X (2015): The Role and Potential Therapeutic Application of Myeloid-Derived Suppressor Cells in Allo- and Autoimmunity. Mediators Inflamm 2015: 421927.
9.
Lai D, Qin C, Shu Q (2014): Myeloid-Derived Suppressor Cells in Sepsis. Biomed Res Int 2014: 598654.
10.
Katoh H, Watanabe M (2015): Myeloid-Derived Suppressor Cells and Therapeutic Strategies in Cancer. Mediators Inflamm 2015: 159269.
11.
Vetsika EK, Koinis F, Gioulbasani M, et al. (2014): A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. J Immunol Res 2014: 659294.
12.
Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012): Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12: 253-268.
13.
Dolcetti L, Peranzoni E, Ugel S, et al. (2010): Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 40: 22-35.
14.
Lechner MG, Megiel C, Russell SM, et al. (2011): Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Translat Med 9: 90.
15.
Kapka-Skrzypczak L, Wolinska E, Szparecki G, et al. (2015): The immunohistochemical analysis of membrane-bound CD55, CD59 and fluid-phase FH and FH-like complement inhibitors in cancers of ovary and corpus uteri origin. Cent Eur J Immunol 40: 349-353.
16.
Youn JI, Nagaraj S, Collazo M, Gabrilovich D (2008): Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181: 5791-5802.
17.
Ning G, She L, Lu L, et al. (2015): Analysis of Monocytic and Granulocytic Myeloid-Derived Suppressor Cells Subsets in Patients with Hepatitis C Virus Infection and Their Clinical Significance. Biomed Res Int 2015: 385378.
18.
Movahedi K, Guilliams M, Van den Bossche J, et al. (2008): Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233-4244.
19.
Dumitru CA, Moses K, Trellakis S, et al. (2012): Neutrophils and granulocytic myeloid-derived suppressor cells: Immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother 61: 1155-1167.
20.
Gabrilovich DI, Nagaraj S (2009): Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174.
21.
Rodríguez PC, Ochoa AC (2008): Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunological reviews. Immunol Rev 222: 180-191.
22.
Pan PY, Ma G, Weber KJ, et al. (2010): Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 70: 99-108.
23.
Malutan AM, Drugan T, Costin N, et al. (2015): Pro-inflammatory cytokines for evaluation of inflammatory status in endometriosis. Centr Eur J Immunol 40: 96-102.
24.
Kusmartsev SA, Li Y, Chen SH (2000): Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 165: 779-785.
25.
Yazan S K, Basil JA, Elkord E (2014): Increased Levels of Granulocytic Myeloid-Derived Suppressor Cells in Peripheral Blood and Tumour Tissue of Pancreatic Cancer Patients.
27.
Garrity T, Pandit R, Wright MA, et al. (1997): Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. Int J Cancer 73: 663-669.
28.
Marx J (2008): Cancer immunology. Cancer’s bulwark against immune attack: MDS cells. Science 319: 154-156.
29.
Ostrand-Rosenberg S, Sinha P (2009): Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer. J Immunol 182: 4499-4506.
30.
Melani C, Chiodoni C, Forni G, Colombo MP (2003): Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102: 2138-2145.
31.
Quail D, Joyce J (2013): Microenvironmental regulation of tumor progression and metastasis. Nat Med 19: 1423-1437.
32.
Kusmartsev S, Su Z, Heiser A, Dannull J (2008): Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 14: 8270-8278.
33.
Kusmartsev S, Eruslanov E, Kubler H, et al. (2008): Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol 181: 346-353.
34.
Serafini P, De Santo C, Marigo I, et al. (2004): Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 53: 64-72.
35.
Eliopoulos AG, Dumitru CD, Wang CC, et al. (2002): Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals. EMBO J 21: 4831-4840.
36.
Sinha P, Clements VK, Ostrand-Rosenberg S (2005): Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174: 636-645.
37.
Trikha P, Carson WE (2014): Signaling pathways involved in MDSC regulation. Biochimica et Biophysica Acta 1846: 55-65.
38.
Wesolowski R, Markowitz J, Carson WE (2013): Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer. J Immunotherapy Cancer 1: 10.
39.
Shi Q, Cheng L, Liu Z, et al. (2015): The p38 MAPK inhibitor SB203580 differentially modulates LPS-induced interleukin 6 expression in macrophages. Cent Eur J Immunol 40: 276-282.
40.
Parker KH, Beury DW, Ostrand-Rosenberg S (2015): Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res 128: 95-139.
41.
Kesarwani P, Murali AK, Al-Khami AA, Mehrotra S (2013): Redox Regulation of T-Cell Function: From Molecular Mechanisms to Significance in Human Health and Disease. Antioxid Redox Signal 18: 1497-1534.
42.
Giallongo C, Parrinello N, Brundo MV, et al. (2015): Myeloid Derived Suppressor Cells in Chronic Myeloid Leukemia. Front Oncol 5: 107.
43.
Mazzoni A, Bronte V, Visintin A, et al. (2002): Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 168: 689-695.
44.
Hanson EM, Clements VK, Sinha P, et al. (2009): Myeloid-derived suppressor cells down-regulate l-selectin expression on CD4+ and CD8+ T cells. J Immunol 183: 937-944.
45.
Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK (2012): Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 22: 275-281.
46.
Li H, Han Y, Guo Q, et al. (2009): Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 182: 240-249.
47.
Brandau S, Moses K, Lang S (2013): The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins? Semin Cancer Biol 23: 171-182.
48.
Siegel RL, Miller KD, Jemal A (2016): Cancer statistics, 2016. CA Cancer J Clin 66: 7-30.
49.
Ferlay J, Shin HR, Bray F, et al. (2010): Estimates of worldwide burden of cancer in 2008: GLOBOCAN. Int J Cancer 127: 2893-2917.
50.
Navaneelan T (2015): Trends in the incidence and mortality of female reproductive system cancers. Health at a Glance. Statistics Canada catalogue no. 82-624-X.
51.
Permuth-Wey J, Sellers TA (2009): Epidemiology of ovarian cancer. Methods Mol Biol 472: 413-437.
53.
Diaz-Montero CM, Finke J, Montero AJ (2014): Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin Oncol 41: 174-184.
54.
Vanderstraeten A, Luyten C, Verbist G, et al. (2014): Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. Cancer Immunol Immunother 63: 545-557.
55.
Kawano M, Mabuchi S, Matsumoto Y, et al. (2015): The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer. Sci Rep 5: 18217.
56.
Clark TG, Stewart ME, Altman DG, et al. (2001): A prognostic model for ovarian cancer. Br J Cancer 85: 944-952.
57.
Agarwal R, Kaye SB (2005): Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann Oncol 16: 4-6.
58.
Wouters M, Dijkgraaf E, Kuijjer M, et al. (2014): Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer. Oncoimmunology 12: e962397.
59.
Makar AP, Baekelandt M, Tropé CG, Kristensen GB (1995): The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III.
61.
Solito S, Marigo I, Pinton L, et al. (2014): Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 1319: 47-65.
62.
Charbonneau B, Goode EL, Kalli KR, et al. (2013): The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol 33: 137-164.
63.
Ugel S, De Sanctis F, Mandruzzato S, Bronte V (2015): Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest 125: 3365-3376.
64.
Lavoué V, Thédrez A, Levìque J, et al. (2013): Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med 11: 147.
65.
Wertel I, Nowicka A, Rogala E, Kotarski J (2011): Peritoneal immune system in patients with advance epithelial ovarian cancer. Int Rev Immunol 30: 87-101.
66.
Obermajer N, Muthuswamy R, Odunsi K, et al. (2011): PGE2-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 71: 7463-7470.
67.
Eruslanov E, Neuberger M, Daurkin I, et al. (2011): Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer 130: 1109-1119.
68.
Kajiyama H, Shibata K, Terauchi M, et al. (2008): Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 122: 91-99.
69.
Wong JL, Obermajer N, Odunsi K, et al. (2016): Synergistic COX2 Induction by IFN and TNF Self-Limits Type-1 Immunity in the Human Tumor Microenvironment. Cancer Immunol Res 4: 303-311.
70.
Reinartz S, Schumann T, Finkernagel F, et al. (2014): Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer 134: 32-42.
71.
Conejo-Garcia JR, Benencia F, Courreges MC, et al. (2004): Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 10: 950-958.
72.
Conejo-Garcia JR, Buckanovich RJ, Benencia F, et al. (2005): Vascular leukocytes contribute to tumor vascularization. Blood 105: 679-681.
73.
Bak SP, Alonso A, Jo Turk M, Berwin B (2008): Murine ovarian cancer vascular leukcoytes require murine ovarian cancer require arginasa-1 activity for T-cell suppression. Mol Immunol 46: 258-268.
74.
Cui TX, Kryczek I, Zhao L, et al. (2013): Myeloid derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 39: 611-621.
75.
Savina A, Jancic C, Hugues S, et al. (2006): NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell 126: 205-218.
76.
Jancic C, Savina A, Wasmeier C, et al. (2007): Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes. Nat Cell Biol 9: 367-378.
77.
Segal BH, Han W, Bushey JJ, et al. (2010): NADPH oxidase limits innate immune responses in the lungs in mice. PLoS One 5: e9631.
78.
Romani L, Fallarino F, De Luca A, et al. (2008): Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 451: 211-215.
79.
Godoy HE, Khan AN, Vethanayagam RR, et al. (2013): Myeloid-Derived Suppressor Cells Modulate Immune Responses Independently of NADPH Oxidase in the Ovarian Tumor Microenvironment in Mice. PLoS One 8: e69631.74.
80.
Kubatova A, Erdem A, Erdem M, et al. (2015): Serum cytokine and growth factor levels in patients with endometriosis. Centr Eur J Immunol 38: 500-504.
81.
Gobbo J, Marcion G, Cordonnier M, et al. (2015): Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer. J Natl Cancer Inst 108: 330.
82.
Rieber N, Wecker I, Neri D, et al. (2014): Extracorporeal photopheresis increases neutrophilic myeloid-derived suppressor cells in patients with GvHD. Bone Marrow Transplant 49: 545-552.
83.
Obermajer N, Wong JL, Edwards RP, et al. (2013): Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling. J Exp Med 210: 1433-1445.
84.
Baharlou R, Atashzar MR, Vasmehjani AA, et al. (2016): Reduced levels of T-helper 17-associated cytokines in the serum of patients with breast cancer: indicators for following the course of disease. Centr Eur J Immunol 41: 78-85.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
